Related Experiment Video

Updated: May 8, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes

S Mudaliar1

  • 1Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA, USA. smudaliar@vapop.ucsd.edu

International Journal of Clinical Practice
|August 20, 2013
PubMed

Insights

Early interventions targeting beta-cell function decline in prediabetes and type 2 diabetes mellitus (T2DM) may delay disease progression. Lifestyle changes and specific medications can preserve beta-cell function, potentially improving glucose control and reducing complications.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Research

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and progressive beta-cell dysfunction.
  • Significant beta-cell function loss occurs early, even during the prediabetic state, preceding T2DM diagnosis.
  • Current treatments often fail to halt beta-cell decline, necessitating insulin therapy over time.

Purpose of the Study:

  • To review evidence on interventions that preserve or enhance beta-cell function in T2DM and prediabetes.
  • To explore the potential of early interventions to alter the natural course of T2DM.
  • To assess the impact of preserving beta-cell function on glycaemic control and complication incidence.

Main Methods:

  • Literature search of original research and review articles in PubMed (January 2000 - August 2012).
  • Analysis of data from prospective studies and clinical trials.
  • Focus on interventions affecting beta-cell function in the context of T2DM and prediabetes.

Main Results:

  • Lifestyle modifications and certain antihyperglycaemic medications (TZDs, GLP-1 agonists, DPP-4 inhibitors) show potential to preserve or enhance beta-cell function.
  • Early initiation of these interventions may reverse or delay T2DM progression in prediabetic individuals.
  • Improved beta-cell function is associated with more durable glucose control and potentially reduced diabetic complications.

Conclusions:

  • Early intervention with lifestyle changes and beta-cell preserving medications is a promising strategy for T2DM management.
  • Preserving beta-cell function may offer long-term benefits in glycaemic control and complication prevention.
  • Further long-term studies are required to validate these findings and their clinical implications.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...